Penserra Capital Management LLC Invests $2.29 Million in ADMA Biologics Inc (NASDAQ:ADMA)

Penserra Capital Management LLC acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 115,603 shares of the biotechnology company's stock, valued at approximately $2,293,000.

Several other large investors also recently modified their holdings of ADMA. Bank of New York Mellon Corp grew its stake in shares of ADMA Biologics by 10.8% in the 4th quarter. Bank of New York Mellon Corp now owns 1,521,166 shares of the biotechnology company's stock valued at $26,088,000 after buying an additional 147,748 shares during the period. Mutual of America Capital Management LLC grew its stake in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after acquiring an additional 751 shares during the period. Jones Financial Companies Lllp grew its stake in ADMA Biologics by 303.4% in the fourth quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 4,312 shares during the period. Charles Schwab Investment Management Inc. grew its stake in ADMA Biologics by 1.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company's stock valued at $41,851,000 after acquiring an additional 38,761 shares during the period. Finally, Victory Capital Management Inc. grew its stake in ADMA Biologics by 52.8% in the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after acquiring an additional 38,002 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ADMA. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial lifted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock valued at $9,644,269 over the last three months. 3.50% of the stock is currently owned by insiders.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA traded up $0.04 during midday trading on Friday, reaching $18.51. The company had a trading volume of 1,954,226 shares, compared to its average volume of 3,682,137. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The stock has a market cap of $4.42 billion, a P/E ratio of 21.78 and a beta of 0.43. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67. The company's 50 day moving average price is $19.68 and its 200 day moving average price is $18.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the previous year, the company posted $0.08 EPS. ADMA Biologics's revenue for the quarter was up 40.2% on a year-over-year basis. As a group, sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.